HC Wainwright Lowers Codexis (NASDAQ:CDXS) Price Target to $15.00

Codexis (NASDAQ:CDXSGet Rating) had its price objective decreased by HC Wainwright from $25.00 to $15.00 in a note issued to investors on Monday, The Fly reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 148.76% from the stock’s current price.

CDXS has been the topic of a number of other research reports. Piper Sandler decreased their target price on shares of Codexis from $35.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, July 14th. Cowen dropped their target price on Codexis from $39.00 to $21.00 and set an “outperform” rating for the company in a report on Friday, July 15th. Cowen decreased their price target on Codexis from $39.00 to $21.00 in a research note on Friday, July 15th. Craig Hallum dropped their price objective on Codexis from $42.00 to $19.00 in a research note on Friday, July 15th. Finally, Benchmark set a $20.00 target price on shares of Codexis in a report on Tuesday, July 19th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Codexis Price Performance

Shares of CDXS opened at $6.03 on Monday. The firm has a market cap of $394.93 million, a P/E ratio of -12.56 and a beta of 1.49. Codexis has a 1 year low of $4.81 and a 1 year high of $41.91. The stock has a 50 day simple moving average of $6.16 and a two-hundred day simple moving average of $8.52.

Insider Activity

In related news, Director John J. Nicols sold 39,000 shares of Codexis stock in a transaction on Monday, August 15th. The shares were sold at an average price of $8.78, for a total value of $342,420.00. Following the sale, the director now owns 1,022,679 shares in the company, valued at $8,979,121.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Codexis news, Director John J. Nicols sold 39,000 shares of the firm’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $8.78, for a total value of $342,420.00. Following the completion of the sale, the director now directly owns 1,022,679 shares in the company, valued at $8,979,121.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John J. Nicols sold 35,716 shares of Codexis stock in a transaction that occurred on Thursday, October 6th. The shares were sold at an average price of $5.99, for a total value of $213,938.84. Following the sale, the director now directly owns 982,892 shares in the company, valued at $5,887,523.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 148,932 shares of company stock valued at $1,085,738. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Codexis

A number of institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in shares of Codexis in the 1st quarter worth about $33,000. Lazard Asset Management LLC bought a new stake in Codexis during the second quarter worth about $66,000. US Bancorp DE grew its holdings in Codexis by 21.1% in the third quarter. US Bancorp DE now owns 14,586 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,540 shares during the period. SG Americas Securities LLC bought a new position in shares of Codexis during the second quarter valued at approximately $109,000. Finally, Strs Ohio lifted its holdings in shares of Codexis by 65.2% during the second quarter. Strs Ohio now owns 10,900 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 4,300 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Codexis Company Profile

(Get Rating)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Recommended Stories

The Fly logo

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.